دورية أكاديمية
أعرض في EDS

Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial.

التفاصيل البيبلوغرافية
العنوان: Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial.
المؤلفون: Kahn SE; Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, VA Puget Sound Health Care System and University of Washington, Seattle., Deanfield JE; Institute of Cardiovascular Science, University College London, London, U.K., Jeppesen OK; Novo Nordisk A/S, Søborg, Denmark., Emerson SS; Department of Biostatistics, University of Washington, Seattle, WA., Boesgaard TW; Novo Nordisk A/S, Søborg, Denmark., Colhoun HM; Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, U.K., Kushner RF; Department of Medicine, Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, IL., Lingvay I; Department of Internal Medicine/Endocrinology and Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX., Burguera B; Endocrinology & Metabolism Institute, Cleveland Clinic, Cleveland, OH., Gajos G; Department of Coronary Artery Disease and Heart Failure, Jagiellonian University Medical College, Kraków, Poland., Horn DB; Department of Surgery, John P. and Katherine G. McGovern Medical School, University of Texas, Houston, TX., Hramiak IM; Western University, London, Ontario, Canada., Jastreboff AM; Endocrinology and Metabolism, Department of Medicine, and Pediatric Endocrinology, Department of Pediatrics, Yale School of Medicine, New Haven, CT., Kokkinos A; First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece., Maeng M; Department of Cardiology, Aarhus University Hospital, and Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Matos ALSA; Novo Nordisk A/S, Søborg, Denmark., Tinahones FJ; Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), CIBERobn, and Department of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, Malaga University, Málaga, Spain., Lincoff AM; Department of Cardiovascular Medicine, Cleveland Clinic, and Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH., Ryan DH; Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, VA Puget Sound Health Care System and University of Washington, Seattle.; Pennington Biomedical Research Center, Baton Rouge, LA.
مؤلفون مشاركون: SELECT Trial Investigators
المصدر: Diabetes care [Diabetes Care] 2024 Aug 01; Vol. 47 (8), pp. 1350-1359.
نوع المنشور: Journal Article; Randomized Controlled Trial; Multicenter Study
اللغة: English
بيانات الدورية: Publisher: American Diabetes Association Country of Publication: United States NLM ID: 7805975 Publication Model: Print Cited Medium: Internet ISSN: 1935-5548 (Electronic) Linking ISSN: 01495992 NLM ISO Abbreviation: Diabetes Care Subsets: MEDLINE
أسماء مطبوعة: Publication: Alexandria Va : American Diabetes Association
Original Publication: New York, American Diabetes Assn.
مواضيع طبية MeSH: Glucagon-Like Peptides*/therapeutic use , Overweight*/drug therapy , Overweight*/complications , Obesity*/drug therapy , Obesity*/complications , Blood Glucose*/drug effects , Blood Glucose*/metabolism , Glycated Hemoglobin*/metabolism, Humans ; Male ; Middle Aged ; Female ; Aged ; Double-Blind Method ; Hypoglycemic Agents/therapeutic use
مستخلص: Objective: To determine whether semaglutide slows progression of glycemia in people with cardiovascular disease and overweight or obesity but without diabetes.
Research Design and Methods: In a multicenter, double-blind trial, participants aged ≥45 years, with BMI ≥27 kg/m2, and with preexisting cardiovascular disease but without diabetes (HbA1c <6.5%) were randomized to receive subcutaneous semaglutide (2.4 mg weekly) or placebo. Major glycemic outcomes were HbA1c and proportions achieving biochemical normoglycemia (HbA1c <5.7%) and progressing to biochemical diabetes (HbA1c ≥6.5%).
Results: Of 17,604 participants, 8,803 were assigned to semaglutide and 8,801 to placebo. Mean ± SD intervention exposure was 152 ± 56 weeks and follow-up 176 ± 40 weeks. In both treatment arms mean nadir HbA1c for participants was at 20 weeks. Thereafter, HbA1c increased similarly in both arms, with a mean difference of -0.32 percentage points (95% CI -0.33 to -0.30; -3.49 mmol/mol [-3.66 to -3.32]) and with the difference favoring semaglutide throughout the study (P < 0.0001). Body weight plateaued at 65 weeks and was 8.9% lower with semaglutide. At week 156, a greater proportion treated with semaglutide were normoglycemic (69.5% vs. 35.8%; P < 0.0001) and a smaller proportion had biochemical diabetes by week 156 (1.5% vs. 6.9%; P < 0.0001). The number needed to treat was 18.5 to prevent a case of diabetes. Both regression and progression were dependent on glycemia at baseline, with the magnitude of weight reduction important in mediating 24.5% of progression and 27.1% of regression.
Conclusions: In people with preexisting cardiovascular disease and overweight or obesity but without diabetes, long-term semaglutide increases regression to biochemical normoglycemia and reduces progression to biochemical diabetes but does not slow glycemic progression over time.
(© 2024 by the American Diabetes Association.)
التعليقات: Comment in: Diabetes Care. 2024 Aug 1;47(8):1322-1324. doi: 10.2337/dci24-0057. (PMID: 38907681)
References: Diabetes Care. 2022 Oct 1;45(10):2396-2405. (PMID: 35724304)
Diabetes Care. 2009 Jul;32(7):1327-34. (PMID: 19502545)
Diabetes Care. 2024 Apr 1;47(4):580-588. (PMID: 38211595)
N Engl J Med. 2017 Feb 16;376(7):641-651. (PMID: 28199805)
N Engl J Med. 2012 Jul 26;367(4):319-28. (PMID: 22686416)
Diabetes Care. 2004 Jan;27(1):155-61. (PMID: 14693982)
Diabetes. 2005 Apr;54(4):1150-6. (PMID: 15793255)
Diabetologia. 2020 Jul;63(7):1324-1332. (PMID: 32291466)
Diabetes Care. 2015 Jan;38(1):51-8. (PMID: 25336746)
Diabetes Care. 2024 Jan 1;47(Suppl 1):S20-S42. (PMID: 38078589)
J Clin Invest. 1999 Sep;104(6):787-94. (PMID: 10491414)
N Engl J Med. 2002 Feb 7;346(6):393-403. (PMID: 11832527)
Mol Metab. 2022 Mar;57:101351. (PMID: 34626851)
Diabetes Care. 2021 Aug 30;:. (PMID: 34462270)
N Engl J Med. 2011 Mar 24;364(12):1104-15. (PMID: 21428766)
Am Heart J. 2020 Nov;229:61-69. (PMID: 32916609)
N Engl J Med. 2010 Apr 22;362(16):1463-76. (PMID: 20228402)
Diabetes. 2002 Jul;51(7):2170-8. (PMID: 12086947)
Diabetologia. 2006 Feb;49(2):289-97. (PMID: 16391903)
N Engl J Med. 2023 Dec 14;389(24):2221-2232. (PMID: 37952131)
J Diabetes Complications. 2013 Mar-Apr;27(2):150-7. (PMID: 23140912)
Obesity (Silver Spring). 2023 Jan;31(1):111-122. (PMID: 36502289)
Lancet. 2006 Sep 23;368(9541):1096-105. (PMID: 16997664)
Stat Med. 2019 Oct 30;38(24):4828-4840. (PMID: 31411779)
N Engl J Med. 2001 May 3;344(18):1343-50. (PMID: 11333990)
N Engl J Med. 2022 Sep 22;387(12):1063-1074. (PMID: 36129996)
N Engl J Med. 2012 Aug 23;367(8):695-704. (PMID: 22913680)
Diabetes Care. 2003 Jan;26 Suppl 1:S5-20. (PMID: 12502614)
Diabetes Care. 1997 Apr;20(4):537-44. (PMID: 9096977)
Lancet. 2019 Jul 13;394(10193):121-130. (PMID: 31189511)
N Engl J Med. 2010 Apr 22;362(16):1477-90. (PMID: 20228403)
Lancet. 2017 Apr 8;389(10077):1399-1409. (PMID: 28237263)
Nature. 2006 Dec 14;444(7121):840-6. (PMID: 17167471)
معلومات مُعتمدة: Janssen; The SELECT Trial Investigators; Squibb; Bayer; GPP 2022 Novo Nordisk A/S; NNF22OC0074083 Novo Nordisk; Eli Lilly & Company; Verve Therapeutics; Philips
المشرفين على المادة: 62340-29-8 (Glucagon-Like Peptides)
53AXN4NNHX (semaglutide)
0 (Blood Glucose)
0 (Glycated Hemoglobin)
0 (Hypoglycemic Agents)
تواريخ الأحداث: Date Created: 20240622 Date Completed: 20240725 Latest Revision: 20240729
رمز التحديث: 20240729
مُعرف محوري في PubMed: PMC11282386
DOI: 10.2337/dc24-0491
PMID: 38907683
قاعدة البيانات: MEDLINE
الوصف
تدمد:1935-5548
DOI:10.2337/dc24-0491